An Antibody That Clogs Up A Key Defense Of Cancer Cells
It's always risky to pin high hopes on cancer drugs that haven't been tested in people yet. But scientists at New York's Memorial Sloan-Kettering Cancer Center are seeing startling results with a new approach. Many internal tumors manage to shrug off chemotherapy by adding more of the so-called receptors that snare an important protein called epidermal growth factor (EGF). The malignant cells that chemotherapy just damages, but doesn't kill, are thus able to grab additional EGF and quickly repair themselves.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis
- Greenwich Mansion Listings Pulled to Wait for a Better Day
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- U.S. Stocks Climb With Treasuries as Dollar Slides: Markets Wrap